Amarin Revives Lawsuit Against Hikma Over Vascepa

Amarin Pharma's patent lawsuit against Hikma Pharmaceuticals regarding the generic version of Vascepa, a heart medication, has been revived by the U.S. Court of Appeals for the Federal Circuit. The lawsuit involves the concept of 'skinny labels,' allowing generic drugmakers to market drugs for approved indications of brand-name drugs while omitting others. The court ruled that Hikma's actions may have induced infringement of Amarin's patents by promoting the generic drug without acknowledging its label limitations. Vascepa, Amarin's significant product, saw a decline in sales as generics entered the market, leading to legal disputes over patent rights and marketing practices. The court's decision highlights the ongoing challenges faced by generics in marketing drugs with 'carved-out' labels, emphasizing the importance of label accuracy and marketing compliance in patent infringement cases.